Stifel Financial Corp Has $994,000 Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Stifel Financial Corp increased its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 19.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 178,702 shares of the medical technology company’s stock after purchasing an additional 29,411 shares during the quarter. Stifel Financial Corp owned approximately 0.13% of Alphatec worth $994,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ATEC. SG Americas Securities LLC grew its holdings in shares of Alphatec by 44.6% in the 2nd quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company’s stock valued at $151,000 after acquiring an additional 4,472 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Alphatec by 16.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 374,742 shares of the medical technology company’s stock worth $3,916,000 after purchasing an additional 53,541 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Alphatec by 15.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,243 shares of the medical technology company’s stock worth $285,000 after purchasing an additional 3,664 shares in the last quarter. AM Investment Strategies LLC acquired a new stake in shares of Alphatec in the 2nd quarter valued at approximately $209,000. Finally, F M Investments LLC bought a new position in shares of Alphatec in the second quarter valued at $3,284,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $9.12 on Tuesday. The firm has a market cap of $1.29 billion, a P/E ratio of -7.13 and a beta of 1.38. The business’s 50 day moving average is $8.45 and its 200-day moving average is $8.09. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Barclays upped their price target on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Needham & Company LLC reiterated a “buy” rating and set a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. Lake Street Capital cut their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.